摘要
背景与目的探讨中药北豆根提取物的体内抗肿瘤作用和免疫学调节作用机制。材料与方法采用水提取、醇提取及水回流等方法对北豆根进行成分分离。采用四甲基偶氮唑蓝[3-(4,5-dimethy-2-thiazoly)-2,5-diphenyl-2-tetrazoliumbromide,MTT]显色法分析北豆根提取物对肿瘤细胞和淋巴细胞增殖反应的作用。采用中性红法检测了北豆根提取物对小鼠巨噬细胞吞噬功能的影响。采用皮下接种肿瘤细胞建立荷瘤小鼠动物模型,采用北豆根提取物灌胃,观察北豆根提取物对小鼠的体内抗肿瘤作用和免疫调节作用。结果北豆根乙醇提取物(RME)比水提取物(RMW)具有更强的抑瘤活性,醇提取物中的PE2成分可能是北豆根的主要抗肿瘤活性部分。经北豆根提取物PE2灌胃后的荷瘤小鼠,与对照组荷瘤小鼠相比其胸腺指数、脾指数明显增加;腹腔巨噬细胞吞噬功能和细胞因子分泌功能增强;NK细胞活性增加;一般情况较对照组小鼠好;肿瘤生长缓慢而局限;生存期明显延长。结论PE2是北豆根抗肿瘤作用的主要有效部分,PE2体内也具有抗肿瘤作用,能通过增强荷瘤小鼠巨噬细胞的吞噬功能,增强NK细胞和小鼠脾细胞的活性,而发挥抗肿瘤作用。
BACKGROUND & AIM: To study the antitumor activity and immunoregulatory activity of Chinese medicinal herb Rhizoma Menipermi extracts in vivo. MATERIAL AND METHODS: The chemical composition of Rhizoma Menipermi extract was separated with water, ethanol extraction and distillation methods. The suppressive effect of Rhizoma Menipenni extracts on the proliferation of tumor cells were assayed in vitro using MTTcolorimetric method. The effect of Rhizoma Menipermi extracts on lymphocytes and the effect on the phagocytosis of mouse peritoneal macrophages were studied using MTT colorimetric method and neutral red method. The tumor bearing mouse model was constructed by injecting tumor cells subcutaneously. Then PE2 from Rhizoma Menipermi extract was given to the mouse orally to observe its antitumor activity and immunoregulatory activity in vivo. RESULTS: Rhizoma Menipermi extracts RMW and RME markedly inhibited the proliferation of tumor cells such as K562. The effect of RME was stronger than RMW.The PE2 constituent purified from RME might be the main antitumor active part of Rhizoma Menipermi as shown by antitumor test in ritro. After treatment with PE2, the general condition of the test mice was much better than that of control mice, with tumor growing more slowly and life prolonged. CONCLUSION: PE2 might be the main antitumor active part of Rhizoma Menipermi. PE2 also had antitumor effect in vivo. PE2 could exert antitumor effect in vivo by enhancing the phagocytosis of macrophages and by enhancing NK cells activity.
出处
《癌变.畸变.突变》
CAS
CSCD
2006年第5期351-354,共4页
Carcinogenesis,Teratogenesis & Mutagenesis
基金
国家自然基金
(C03050205)
河北省自然基金(C2004000610)